JP2014508759A - シアリル化抗体の生産の方法 - Google Patents

シアリル化抗体の生産の方法 Download PDF

Info

Publication number
JP2014508759A
JP2014508759A JP2013554892A JP2013554892A JP2014508759A JP 2014508759 A JP2014508759 A JP 2014508759A JP 2013554892 A JP2013554892 A JP 2013554892A JP 2013554892 A JP2013554892 A JP 2013554892A JP 2014508759 A JP2014508759 A JP 2014508759A
Authority
JP
Japan
Prior art keywords
antibody
seq
domain
sequence
antiabeta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013554892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508759A5 (enExample
Inventor
ブランシユ，フランシス
カムロン，ベアトリス
ジユネ，ブリユノ
スブリエ，フアブリエンヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2014508759A publication Critical patent/JP2014508759A/ja
Publication of JP2014508759A5 publication Critical patent/JP2014508759A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013554892A 2011-02-24 2012-02-23 シアリル化抗体の生産の方法 Pending JP2014508759A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305200.5 2011-02-24
EP11305200 2011-02-24
EP11306090 2011-09-01
EP11306090.9 2011-09-01
PCT/EP2012/053065 WO2012113863A1 (en) 2011-02-24 2012-02-23 Method of production of sialylated antibodies

Publications (2)

Publication Number Publication Date
JP2014508759A true JP2014508759A (ja) 2014-04-10
JP2014508759A5 JP2014508759A5 (enExample) 2015-02-19

Family

ID=45774189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013554892A Pending JP2014508759A (ja) 2011-02-24 2012-02-23 シアリル化抗体の生産の方法

Country Status (6)

Country Link
US (1) US20140046032A1 (enExample)
EP (1) EP2678357A1 (enExample)
JP (1) JP2014508759A (enExample)
AR (1) AR085302A1 (enExample)
TW (1) TW201241182A (enExample)
WO (1) WO2012113863A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515524A (ja) * 2017-01-31 2020-05-28 サノフイＳａｎｏｆｉ ベータアミロイドペプチドのプロトフィブリル形態に特異的な抗体の神経細胞保護作用
JP2021522216A (ja) * 2018-04-20 2021-08-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 高度にシアル化された自己抗体およびその使用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
RU2711935C2 (ru) 2013-03-11 2020-01-23 Джензим Корпорейшн Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
EP2991666B1 (en) 2013-05-02 2020-03-25 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
JP6594860B2 (ja) * 2013-05-29 2019-10-23 エフ．ホフマン−ラ ロシュ アーゲー シアル酸付加の定量的調節
EP3017057B1 (en) 2013-07-05 2019-10-02 F.Hoffmann-La Roche Ag Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) * 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PL3129067T3 (pl) 2014-03-19 2023-05-08 Genzyme Corporation Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
AU2015293949B2 (en) 2014-07-21 2019-07-25 Teknologian Tutkimuskeskus Vtt Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
EP3037527A1 (en) * 2014-12-22 2016-06-29 F. Hoffmann-La Roche AG Sialyltransferase without CMP-dependent sialidase activity
CN107429237B (zh) 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
TW202325853A (zh) * 2021-11-09 2023-07-01 美商安進公司 治療性蛋白之生產
WO2025101901A1 (en) * 2023-11-10 2025-05-15 The Board Of Trustees Of The Leland Stanford Junior University Use of sialylated ivig or igg fc region-containing protein for preventing or treating respiratory virus diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504569A (ja) * 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
JP2010510801A (ja) * 2006-11-28 2010-04-08 サントリオン 生物学的活性が向上した修飾可溶性ＦＧＦ受容体Ｆｃ融合物
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
WO2010130946A1 (fr) * 2009-05-12 2010-11-18 Sanofi-Aventis Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
EP1427828B1 (en) 2001-09-14 2010-04-28 Cellectis Random integration of a polynucleotide after in vivo linearization
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
ATE536373T1 (de) 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008057634A2 (en) 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
MX2008007477A (es) 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
EP2815768A3 (en) 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PE20090993A1 (es) 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
EP2650308A3 (en) 2007-10-05 2014-11-12 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
JP2011500059A (ja) 2007-10-15 2011-01-06 セントコア・オーソ・バイオテツク・インコーポレーテツド ヒト抗アミロイド抗体、組成物、方法及び使用
WO2009054537A1 (ja) 2007-10-25 2009-04-30 Kagoshima University アミロイドβペプチドのミミック分子を用いたペプチドワクチン
AU2008317354B2 (en) 2007-10-25 2014-04-10 Ospedale San Raffaele S.R.L. Methods and compositions for targeted integration
CN104098695B (zh) 2007-10-29 2018-09-07 道健康生活医药株式会社 抗体及其应用
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
EP2222705B1 (en) 2007-12-11 2014-10-22 Glaxo Group Limited Antigen binding proteins
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504569A (ja) * 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2010510801A (ja) * 2006-11-28 2010-04-08 サントリオン 生物学的活性が向上した修飾可溶性ＦＧＦ受容体Ｆｃ融合物
WO2010130946A1 (fr) * 2009-05-12 2010-11-18 Sanofi-Aventis Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 286, JPN6017006279, 2001, pages 243 - 249, ISSN: 0003505805 *
SCIENCE, vol. 320, JPN6017006281, 2008, pages 373 - 376, ISSN: 0003505806 *
THE JOURNAL OF IMMUNOLOGY, vol. 157, JPN6015007484, 1996, pages 4963 - 4969, ISSN: 0003226087 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515524A (ja) * 2017-01-31 2020-05-28 サノフイＳａｎｏｆｉ ベータアミロイドペプチドのプロトフィブリル形態に特異的な抗体の神経細胞保護作用
JP2021522216A (ja) * 2018-04-20 2021-08-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 高度にシアル化された自己抗体およびその使用

Also Published As

Publication number Publication date
TW201241182A (en) 2012-10-16
WO2012113863A1 (en) 2012-08-30
EP2678357A1 (en) 2014-01-01
AR085302A1 (es) 2013-09-18
US20140046032A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
US20140046032A1 (en) Method of production of sialylated antibodies
JP7357382B2 (ja) 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
Vattepu et al. Sialylation as an important regulator of antibody function
AU2016372934B2 (en) Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
DK1896071T3 (en) Methods and compositions with increased therapeutic activity
AU2017285764B2 (en) Anti-myostatin antibodies and methods of use
CA2674239C (en) Methods and vectors for generating asialylated immunoglobulins
US20100189714A1 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2963760A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR20100074220A (ko) Ｃｄｒ의 아미노산 치환에 의해 항체의 등전점을 개변하는 방법
TWI780097B (zh) 於活體外進行抗體之糖基化工程
CN103582650A (zh) 用于制备具有改善性质的含Fc多肽的方法
JP2024518545A (ja) Ｔｒｅｍ２のアゴニスト
CN110100007B (zh) 用于体外糖工程化抗体的酶的再使用
TWI781973B (zh) 用於以活體外進行抗體糖基化工程之方法
MX2013015061A (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso para el tratamiento del cancer.
JP2010512306A (ja) 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
NZ597651A (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2026513101A (ja) エフェクター機能が強化された糖鎖改変Ｆｃ変異ポリペプチド
HK40123043A (zh) 用於体外糖工程化抗体的方法
HK40106545A (zh) 用於体外糖工程化抗体的方法
HK40011892B (zh) 用於体外糖工程化抗体的酶的再使用
TW201305336A (zh) 具作用功能的抗ｃｘｃｒ４抗體及其供治療癌症之用途
HK1191032A (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141222

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161220

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170224